Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.
Intellia Therapeutics (NTLA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Intellia Therapeutics's actual EPS was -$1.10, beating the estimate of -$1.31 per share, resulting in a 15.91% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
